Analyst Reco. Enfusion, Inc.

Equities

ENFN

US2928121043

Market Closed - Nyse Other stock markets 01:30:02 07/05/2024 am IST			5-day change	1st Jan Change
9.78 ^USD	+2.19%		+2.95%	+0.82%

14/03	Enfusion Shares Slip After Short-Seller Spruce Point Warns of 'Financial Restatement Risk'	MT
13/03	BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating	13/03	MT
Goldman Sachs Downgrades Enfusion to Sell From Neutral, Trims Price Target to $8 From $9	28/02	MT
JPMorgan Downgrades Enfusion to Underweight From Neutral, Cut Price Target to $9 From $11	30/01	MT
UBS Adjusts Enfusion Price Target to $9.50 From $9, Maintains Neutral Rating	08/11	MT
UBS Initiates Coverage on Enfusion With Neutral Rating, $9 Price Target	07/11	MT
Goldman Sachs Adjusts Enfusion's Price Target to $10 From $11.50, Keeps Neutral Rating	09/23/09	MT
Morgan Stanley Adjusts Enfusion Price Target to $11 From $12, Maintains Overweight Rating	09/23/09	MT
Piper Sandler Adjusts Price Target on Enfusion to $9 From $11, Maintains Neutral Rating	22/23/22	MT
Credit Suisse Trims Enfusion's Price Target to $11 From $14, Keeps Neutral Rating	10/23/10	MT
Piper Sandler Starts Enfusion at Neutral With $11 Price Target	03/23/03	MT
JPMorgan Starts Enfusion at Neutral With $12 Price Target	15/23/15	MT
Goldman Sachs Adjusts Price Target on Enfusion to $11.50 From $9.50, Maintains Neutral Rating	08/23/08	MT
Goldman Sachs Adjusts Price Target on Enfusion to $9.50 From $14, Maintains Neutral Rating	26/23/26	MT
BofA Downgrades Enfusion to Underperform From Neutral, Trims Price Target to $10 From $15	04/23/04	MT
Morgan Stanley Upgrades Enfusion to Overweight From Equalweight, Adjusts Price Target to $12 From $13	03/23/03	MT
Goldman Sachs Adjusts Price Target on Enfusion to $14 From $13, Maintains Neutral Rating	11/22/11	MT
BofA Securities Downgrades Enfusion to Neutral From Buy, Adjusts Price Target to $15 From $17	03/22/03	MT
Goldman Sachs Adjusts Enfusion's Price Target to $13 From $12, Maintains Neutral Rating	10/22/10	MT
Morgan Stanley Raises Enfusion's Price Target to $13 From $8, Maintains Equalweight Rating	10/22/10	MT
Goldman Sachs Lowers Enfusion's Price Target to $12 From $14, Neutral Rating Kept	14/22/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Enfusion, Inc.

Equities

ENFN

US2928121043

Analyst Reco.

Filters